A review on Bevacizumab for the treatment of Glioblastoma

Abstract

Background: A targeted drug therapy like bevacizumab also known as monoclonal antibody used now-a-days in the treatment of glioblastoma which contributes significantly in the progression free survival. Purpose: The goal of this review article was to assess the effectiveness and safety of a targeted therapy drug like bevacizumab, in glioblastoma patients and monitor their progress or improvement through observing the drug's available data. Method: The article was searched by using all the associated terms for bevacizumab and glioblastoma through electronic databases such as PubMed, Web of science and Embase. A comprehensive analysis was conducted on all the relevant studies. Result: Clinical trials and articles have demonstrated that bevacizumab can significantly improve the progression free survival rate of PFS for the glioblastoma patients but its effect on overall survival is still unclear. Both single and combination-based bevacizumab therapy are beneficial for the glioblastoma and enhance the patient's quality of life.